TransMedics Group, Inc. (TMDX) EV/FCF Ratio: 21.49x
Is TransMedics Group, Inc.’s EV/FCF ratio high or low?
TransMedics Group, Inc.'s EV/FCF ratio of 21.49x is 80% below its 1-year average of 107.06x, near the low end of its 1-year range (17.49x–316.41x).
As of Saturday, June 20, 2026.
TMDX EV/FCF Ratio Chart
TMDX EV/FCF Ratio Metrics
EV/FCF RATIO
21.49x
EV/FCF RATIO AVG TTM
N/A
EV/FCF RATIO AVG 3Y
N/A
EV/FCF RATIO AVG 5Y
N/A
EV/FCF RATIO AVG 10Y
N/A
EV/FCF RATIO AVG 15Y
N/A
EV/FCF RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
TMDX Competitors' EV/FCF Ratio
| NAME | MARKET CAP | EV/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| TransMedics Group, Inc. (TMDX) | $2.72B | 21.49x | N/A | N/A | N/A |
| DENTSPLY SIRONA Inc. (XRAY)vs › | $2.07B | 40.44x | 41.25x | 32.68x | 28.41x |
| 23andMe Holding Co. (ME)vs › | $15.31M | N/A | N/A | N/A | N/A |
| Bio-Rad Laboratories, Inc. (BIO)vs › | $7.64B | 23.75x | 25.14x | 42.97x | 51.05x |
| Hims & Hers Health, Inc. (HIMS)vs › | $7.91B | 118.80x | 83.66x | 71.67x | 71.67x |
| Tempus AI, Inc. (TEM)vs › | $8.87B | N/A | N/A | N/A | N/A |
| Charles River Laboratories International, Inc. (CRL)vs › | $8.91B | 30.46x | 21.52x | 28.96x | 35.18x |
| Baxter International Inc. (BAX)vs › | $10.27B | 25.09x | 65.92x | 51.53x | 47.28x |
| Walgreens Boots Alliance, Inc. (WBA)vs › | $10.37B | 66.60x | 67.40x | 78.57x | 42.55x |
| Revvity, Inc. (RVTY)vs › | $11.16B | 27.69x | 26.79x | 265.50x | 164.11x |
Cash Flow Valuation Comparison
EV/FCF
21.5x
P/FCF
18.8x
FCF Yield
5.31%
Formula: EV/FCF = Enterprise Value / Free Cash Flow
EV/FCF vs P/FCF:
- EV/FCF accounts for debt and cash through enterprise value
- P/FCF only considers equity value
- EV/FCF can be compared across companies with different debt levels
- Both measure how the market values cash generation
TransMedics Group, Inc. EV/FCF Ratio Formula & Definition
EV/FCF = Enterprise Value / Free Cash Flow (TTM)
Enterprise value to free cash flow compares total company value to the cash the business generates after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
TransMedics Group, Inc. EV/FCF Ratio FAQ
- What is the EV/FCF ratio for TransMedics Group, Inc. (TMDX)?
- The EV/FCF ratio for TMDX stock is 21.49x.
- Is TransMedics Group, Inc.'s EV/FCF ratio high or low?
- TransMedics Group, Inc.'s EV/FCF ratio of 21.49x is 80% below its 1-year average of 107.06x, near the low end of its 1-year range (17.49x–316.41x).
TransMedics Group, Inc. EV/FCF Ratio History
| DATE | EV/FCF RATIO |
|---|---|
| 2026-06-18 | 21.49x |
| 2026-06-17 | 20.16x |
| 2026-06-16 | 20.78x |
| 2026-06-15 | 20.70x |
| 2026-06-12 | 20.09x |
| 2026-06-11 | 20.25x |
| 2026-06-10 | 20.53x |
| 2026-06-09 | 20.42x |
| 2026-06-08 | 19.67x |
| 2026-06-05 | 19.26x |
| 2026-06-04 | 19.72x |
| 2026-06-03 | 19.32x |
| 2026-06-02 | 19.02x |
| 2026-06-01 | 18.80x |
| 2026-05-29 | 18.72x |
| 2026-05-28 | 18.87x |
| 2026-05-27 | 19.43x |
| 2026-05-26 | 19.50x |
| 2026-05-22 | 19.14x |
| 2026-05-21 | 19.12x |
| 2026-05-20 | 18.91x |
| 2026-05-19 | 18.47x |
| 2026-05-18 | 19.00x |
| 2026-05-15 | 17.77x |
| 2026-05-14 | 17.49x |
| 2026-05-13 | 18.00x |
| 2026-05-12 | 17.94x |
| 2026-05-11 | 18.03x |
| 2026-05-08 | 18.88x |
| 2026-05-07 | 20.09x |
| 2026-05-06 | 20.09x |
| 2026-05-05 | 25.35x |
| 2026-05-04 | 29.60x |
| 2026-05-01 | 30.50x |
| 2026-04-30 | 30.74x |
| 2026-04-29 | 30.06x |
| 2026-04-28 | 30.88x |
| 2026-04-27 | 32.99x |
| 2026-04-24 | 33.85x |
| 2026-04-23 | 34.54x |
| 2026-04-22 | 34.99x |
| 2026-04-21 | 33.23x |
| 2026-04-20 | 34.52x |
| 2026-04-17 | 35.36x |
| 2026-04-16 | 33.29x |
| 2026-04-15 | 35.43x |
| 2026-04-14 | 35.30x |
| 2026-04-13 | 34.59x |
| 2026-04-10 | 34.79x |
| 2026-04-09 | 33.32x |
| 2026-04-08 | 33.37x |
| 2026-04-07 | 32.74x |
| 2026-04-06 | 31.97x |
| 2026-04-02 | 30.71x |
| 2026-04-01 | 30.62x |
| 2026-03-31 | 30.32x |
| 2026-03-30 | 28.75x |
| 2026-03-27 | 30.21x |
| 2026-03-26 | 31.17x |
| 2026-03-25 | 32.07x |
| 2026-03-24 | 33.23x |
| 2026-03-23 | 34.20x |
| 2026-03-20 | 34.76x |
| 2026-03-19 | 34.70x |
| 2026-03-18 | 34.54x |
| 2026-03-17 | 38.07x |
| 2026-03-16 | 38.06x |
| 2026-03-13 | 37.69x |
| 2026-03-12 | 37.03x |
| 2026-03-11 | 39.37x |
| 2026-03-10 | 39.95x |
| 2026-03-09 | 41.15x |
| 2026-03-06 | 39.57x |
| 2026-03-05 | 42.77x |
| 2026-03-04 | 45.10x |
| 2026-03-03 | 45.20x |
| 2026-03-02 | 44.90x |
| 2026-02-27 | 44.36x |
| 2026-02-26 | 41.09x |
| 2026-02-25 | 40.26x |
| 2026-02-24 | 42.07x |
| 2026-02-23 | 45.92x |
| 2026-02-20 | 45.78x |
| 2026-02-19 | 45.32x |
| 2026-02-18 | 46.21x |
| 2026-02-17 | 45.64x |
| 2026-02-13 | 44.29x |
| 2026-02-12 | 43.85x |
| 2026-02-11 | 45.46x |
| 2026-02-10 | 47.49x |
| 2026-02-09 | 46.49x |
| 2026-02-06 | 46.06x |
| 2026-02-05 | 44.21x |
| 2026-02-04 | 44.47x |
| 2026-02-03 | 46.28x |
| 2026-02-02 | 45.70x |
| 2026-01-30 | 45.69x |
| 2026-01-29 | 47.38x |
| 2026-01-28 | 48.06x |
| 2026-01-27 | 47.22x |
| 2026-01-26 | 47.50x |
| 2026-01-23 | 46.14x |
| 2026-01-22 | 47.08x |
| 2026-01-21 | 45.63x |
| 2026-01-20 | 48.38x |
| 2026-01-16 | 48.86x |
| 2026-01-15 | 48.97x |
| 2026-01-14 | 48.39x |
| 2026-01-13 | 48.64x |
| 2026-01-12 | 45.92x |
| 2026-01-09 | 46.74x |
| 2026-01-08 | 46.90x |
| 2026-01-07 | 46.80x |
| 2026-01-06 | 45.25x |
| 2026-01-05 | 43.09x |
| 2026-01-02 | 41.88x |
| 2025-12-31 | 41.53x |
| 2025-12-30 | 41.62x |
| 2025-12-29 | 42.00x |
| 2025-12-26 | 42.39x |
| 2025-12-24 | 43.33x |
| 2025-12-23 | 43.74x |
| 2025-12-22 | 44.13x |
| 2025-12-19 | 43.56x |
| 2025-12-18 | 41.33x |
| 2025-12-17 | 41.62x |
| 2025-12-16 | 42.67x |
| 2025-12-15 | 42.03x |
| 2025-12-12 | 43.26x |
| 2025-12-11 | 43.54x |
| 2025-12-10 | 44.76x |
| 2025-12-09 | 45.97x |
| 2025-12-08 | 46.58x |
| 2025-12-05 | 46.55x |
| 2025-12-04 | 47.26x |
| 2025-12-03 | 47.76x |
| 2025-12-02 | 48.32x |
| 2025-12-01 | 51.24x |
| 2025-11-28 | 49.86x |
| 2025-11-26 | 49.67x |
| 2025-11-25 | 49.75x |
| 2025-11-24 | 47.80x |
| 2025-11-21 | 44.66x |
| 2025-11-20 | 42.26x |
| 2025-11-19 | 45.52x |
| 2025-11-18 | 39.98x |
| 2025-11-17 | 38.74x |
| 2025-11-14 | 39.28x |
| 2025-11-13 | 39.47x |
| 2025-11-12 | 40.69x |
| 2025-11-11 | 41.69x |
| 2025-11-10 | 41.78x |
| 2025-11-07 | 40.69x |
| 2025-11-06 | 42.65x |
| 2025-11-05 | 42.48x |
| 2025-11-04 | 41.72x |
| 2025-11-03 | 42.56x |
| 2025-10-31 | 44.87x |
| 2025-10-30 | 46.30x |
| 2025-10-29 | 45.81x |
| 2025-10-28 | 310.00x |
| 2025-10-27 | 316.41x |
| 2025-10-24 | 311.89x |
| 2025-10-23 | 308.13x |
| 2025-10-22 | 286.23x |
| 2025-10-21 | 287.61x |
| 2025-10-20 | 287.07x |
| 2025-10-17 | 281.77x |
| 2025-10-16 | 277.21x |
| 2025-10-15 | 270.03x |
| 2025-10-14 | 266.81x |
| 2025-10-13 | 267.93x |
| 2025-10-10 | 257.60x |
| 2025-10-09 | 270.90x |
| 2025-10-08 | 282.77x |
| 2025-10-07 | 276.04x |
| 2025-10-06 | 273.12x |
| 2025-10-03 | 277.23x |
| 2025-10-02 | 278.12x |
| 2025-10-01 | 275.36x |
| 2025-09-30 | 269.07x |
| 2025-09-29 | 270.10x |
| 2025-09-26 | 272.98x |
| 2025-09-25 | 273.05x |
| 2025-09-24 | 281.30x |
| 2025-09-23 | 288.54x |
| 2025-09-22 | 299.34x |
| 2025-09-19 | 292.66x |
| 2025-09-18 | 289.88x |
| 2025-09-17 | 286.86x |
| 2025-09-16 | 285.32x |
| 2025-09-15 | 273.96x |
| 2025-09-12 | 274.61x |
| 2025-09-11 | 280.27x |
| 2025-09-10 | 258.77x |
| 2025-09-09 | 259.91x |
| 2025-09-08 | 253.60x |
| 2025-09-05 | 249.93x |
| 2025-09-04 | 250.02x |
| 2025-09-03 | 256.78x |
| 2025-09-02 | 267.55x |
| 2025-08-29 | 275.52x |
| 2025-08-28 | 279.66x |
| 2025-08-27 | 281.18x |
| 2025-08-26 | 276.04x |
| 2025-08-25 | 275.55x |
| 2025-08-22 | 286.95x |
| 2025-08-21 | 284.52x |
| 2025-08-20 | 291.70x |
| 2025-08-19 | 293.57x |
| 2025-08-18 | 300.51x |
| 2025-08-15 | 304.95x |
| 2025-08-14 | 310.07x |
| 2025-08-13 | 315.45x |
| 2025-08-12 | 313.32x |
| 2025-08-11 | 304.27x |
| 2025-08-08 | 274.45x |
| 2025-08-07 | 278.07x |
| 2025-08-06 | 284.50x |
| 2025-08-05 | 300.72x |
| 2025-08-04 | 307.17x |
| 2025-08-01 | 288.59x |
| 2025-07-31 | 284.90x |
| 2025-07-30 | 258.55x |
Related Metrics
About TransMedics Group, Inc.
TransMedics Group, Inc. operates as a commercial-stage medical technology enterprise, committed to transforming the landscape of organ transplant therapy for patients worldwide grappling with end-stage organ failure. At the core of their offerings is the Organ Care System (OCS), an innovative, portable solution engineered to perfuse, optimize, and continuously monitor donor organs. This system leverages exclusive, tailored technology to meticulously recreate near-physiological conditions for these vital organs while they remain outside the human body. The OCS suite encompasses specialized modules: OCS LUNG, which facilitates the preservation of standard criteria donor lungs for double-lung transplants; OCS Heart, designed for the extracorporeal perfusion and maintenance of donor hearts; and OCS Liver, dedicated to the preservation of donor livers. Founded in 1998, TransMedics is headquartered in Andover, Massachusetts.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Waleed H. Hassanein